A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.
Abroad (travel likely)RecruitingPHASE1
Conditions
Solid Tumours · Advanced Solid Tumours
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Gosford Hospital, Gosford, New South Wales, Australia
Contact: Principal Investigator (Dr. Craig Kukard)Cancer Care Foundation, Miranda, New South Wales, Australia
Contact: Principal Investigator (Dr Mahmood Alam)Wyong Hospital, Wyong, New South Wales, Australia
Contact: Principal Investigator (Dr. Craig Kukard)Queen Mary Hospital, Hong Kong, Hong Kong
Contact: Principal Investigator (Dr. Roland Ching Yu Leung)Prince of Wales Hospital, Shatin, Hong Kong
Contact: Principal Investigator (Dr. Herbert Loong)Asan Medical Centre, Seoul, South Korea
Contact: Principal Investigator (Prof. JeongEun Kim)Ewha Womans University MokDong Hospital, Seoul, South Korea
Contact: Principal Investigator (Prof. JungMin Jo)Samsung Medical Centre, Seoul, South Korea
Contact: Principal Investigator (Prof JungYong Hong)Severance Hospital, Yonsei University, Health System, Seoul, South Korea
Contact: Principal Investigator (HyoSong Kim)
Study leads
Marinella Messina
Study Director
Racura Oncology Ltd